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Abstract
Background: Women with ovarian cancer can present with a variety of symptoms and signs, and an increasing range
of tests are available for their investigation. A number of international guidelines provide advice for the initial
assessment of possible ovarian cancer in symptomatic women. We systematically identified and reviewed the
consistency and quality of these documents.
Methods: MEDLINE, Embase, guideline-specific databases and professional organisation websites were searched in
March 2018 for relevant clinical guidelines, consensus statements and clinical pathways, produced by professional or
governmental bodies. Two reviewers independently extracted data and appraised documents using the Appraisal for
Guidelines and Research Evaluation 2 (AGREEII) tool.
Results: Eighteen documents from 11 countries in six languages met selection criteria. Methodological quality varied
with two guidance documents achieving an AGREEII score≥ 50% in all six domains and 10 documents scoring ≥50%
for “Rigour of development” (range: 7–96%). All guidance documents provided advice on possible symptoms of ovarian
cancer, although the number of symptoms included in documents ranged from four to 14 with only one symptom
(bloating/abdominal distension/increased abdominal size) appearing in all documents. Fourteen documents provided
advice on physical examinations but varied in both the examinations they recommended and the physical signs they
included. Fifteen documents provided recommendations on initial investigations. Transabdominal/transvaginal
ultrasound and the serum biomarker CA125 were the most widely advocated initial tests. Five distinct testing
strategies were identified based on the number of tests and the order of testing advocated: ‘single test’, ‘dual
testing’, ‘sequential testing’, ‘multiple testing options’ and ‘no testing’.
Conclusions: Recommendations on the initial assessment and investigation for ovarian cancer in symptomatic
women vary considerably between international guidance documents. This variation could contribute to differences in
the way symptomatic women are assessed and investigated between countries. Greater research is needed to evaluate
the assessment and testing approaches advocated by different guidelines and their impact on ovarian cancer
detection.
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Background
Worldwide, ovarian cancer is the seventh most common
cancer in women, with over 200, 000 new cases each
year [1]. While once considered a silent killer, it is now
recognised that symptoms occur in all stages of disease,
although studies differ in the symptoms they report and
the positive predictive value (PPV) they attribute to each
symptom [2–5]. Given the modest PPVs of individual
symptoms, e.g. 0.3% for abdominal pain and 2.5% for
abdominal distension, symptoms alone cannot be used
to diagnose ovarian cancer, but are routinely used to
guide further assessment, including physical examination
and testing [4].
An increasing range of tests are used in the initial investi-
gation of symptomatic women for ovarian cancer, includ-
ing the serum protein biomarker CA125 and imaging
modalities such as transabdominal and transvaginal ultra-
sound, Computed Tomography (CT) and Magnetic Reson-
ance Imaging (MRI). Algorithms that combine test results
with patient characteristics such as age or menopausal
state e.g. the Risk of Malignancy Index (RMI) and the
ADNEX model, have also been developed to help predict
ovarian cancer risk in women presenting with a pelvic
mass [6, 7]. However, debate exists regarding the most
accurate testing strategy for ovarian cancer. There is very
limited research evaluating tests for the initial investigation
of symptoms within the primary care setting [8, 9], where
most women with this condition first present [10].
Given the discrepancies in the research literature on
symptoms and the variety of testing options available,
guidance documents, such as clinical practice guidelines,
consensus statements and clinical care pathways, have
been produced to aid clinicians in making practical deci-
sions regarding the management of women with possible
ovarian cancer. As these documents have the potential
to significantly affect the care and healthcare outcomes
for large numbers of patients, they should be rigorously
developed, grounded in the evidence, and make unam-
biguous recommendations [11, 12].
In this review, we set out to systematically identify and
assess the quality of international guidance documents
covering the initial assessment for ovarian cancer in
symptomatic women. In addition, we aimed to assess the
consistency of guidance documents in terms of the
symptoms and signs they include and the physical exam-
inations and tests they recommend, to gain an insight
into international variation in clinical practice.
Methods
Study selection
We selected documents that provided guidance on the
initial assessment of women presenting with symptoms
that might represent ovarian cancer i.e. an assessment
conducted at the point at which women present with
symptoms and enter a given healthcare system. As such,
guidance documents that solely provided advice on in-
vestigation or management of women after a pelvic mass
had been identified, a specialist referral made or a diag-
nosis of ovarian cancer given, were excluded. As this
review focussed on guidance for women presenting with
symptoms, the most common mode of ovarian cancer
presentation [10, 13], documents which solely provided
advice on screening of asymptomatic women or on the
investigation of incidental pelvic masses, were excluded.
Documents where guidance was limited to sub-groups
of patients, e.g. hereditary cancer syndromes, were also
excluded. Only documents produced by professional or
governmental bodies and published within the ten years
before 13th March 2018 were included. There were no
language restrictions.
Search strategy
Searches were conducted in Embase and MEDLINE. The
MEDLINE search strategy is presented in Additional file 1:
Figure S1. Additional searches were performed in guideline
specific databases, namely, the National Guideline Clearing
House, the Turning Research Into Practice (TRIP) data-
base, the Guidelines International Network, the Canadian
Partnership Against Cancer guidelines database, the Can-
adian Medical Association Infobase and the National Insti-
tute of Health and Care Excellence (NICE) website. All
searches were performed between 1st and 13th of March
2018. The websites of more than 20 relevant international
governmental and professional bodies were hand searched
to supplement the database searches.
Guideline selection
Two reviewers independently assessed titles and abstracts.
Where either reviewer felt that a document met selection
criteria or that it was not possible to exclude on the basis
of title and summary alone, the full text was obtained and
reviewed against the criteria. Disagreements were resolved
by consensus.
Data extraction
Two reviewers, fluent in the language of guideline publi-
cation, independently extracted data using a specifically
developed template. Discrepancies in extraction were re-
solved by consensus.
Information on document characteristics (e.g. develop-
ment body, year of development) and the process of
development was collected. We classified documents
into one of four categories, which best described their
intended purpose and the development process, namely:
(1) full Clinical Practice Guidelines (recommendations
on patient care, informed by a systematic review of the
evidence and taking account of benefits, harms and al-
ternatives) [11]; (2) Short Guides (focused summary
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recommendations for patient care, not necessarily based
on a full systematic literature review); (3) Consensus State-
ments (clinically relevant advice based on the opinion of
an expert panel) [14], and (4) Clinical Pathways (a struc-
tured multidisciplinary plan of patient care, not necessarily
based on a full systematic literature review) [15].
The healthcare system for which a guideline is devel-
oped will influence the recommendations. We applied a
simplified version of the classification system developed
by Bohm et al, categorising healthcare systems into three
groups: National Health Service, National/Social Health
Insurance and Private Health System [16].
Data relating to three components of the initial patient
assessment were extracted: symptoms, physical examina-
tions/signs, and investigations. Documents were cate-
gorised into the following five groups, based on the
number of tests and the order of testing advocated:
‘single test’ i.e. one test advocated; ‘dual testing’ i.e. per-
forming two tests concurrently; ‘sequential testing’ i.e.
performing a second type of investigation (second line)
if the first type of investigation (first line) is abnormal;
‘multiple testing options’ i.e. where a range of investiga-
tion options were presented with no single investigation
being advocated above another; and ‘no testing’ i.e.
where no specific tests were recommended as part of the
initial assessment.
Quality assessment
The AGREEII instrument was used to assess the quality of
guidance development and reporting of included guidance
documents [12]. This validated tool consists of 23 items
divided into six domains: ‘Scope and Purpose’, ‘Stake-
holder Involvement’, ‘Rigour of Development’, ‘Clarity of
Presentation’, ‘Applicability’ and ‘Editorial Independence’.
Each item is rated on a scale from one (criteria not met)
to seven (criteria fully met). While developed for clinical
practice guidelines, it has been used to assess other types
of guidance document [14]. Two reviewers independently
assessed each guidance document using the AGREEII tool.
Assessments were compared and differences of three or
more points per item were discussed and resolved by con-
sensus. Combined scores for each domain were obtained
using the following equation: (Obtained score – minimum
possible score)/(maximum possible score – minimal pos-
sible score) × 100 [12]. We took a score of ≥50% in a
particular domain to indicate ‘satisfactory’ quality [17].
Results
Guideline selection
Our searches identified 846 documents, of which 178
were duplicates. The titles and summaries of 668 docu-
ments were screened, and 62 full text documents were
obtained for further scrutiny. Eighteen documents met
our selection criteria (Fig. 1).
Guideline characteristics
Of the 18 documents that met the selection criteria, two
were developed in continental Europe, five in the United
Kingdom (UK) and Republic of Ireland, three in Scandi-
navia, four in North America and four in Australasia
(Table 1) [18, 21–37]. Thirteen documents were pub-
lished in English. Ten documents were categorised as
full clinical practice guidelines, three as short guides,
four as clinical pathways and one as a consensus state-
ment. Documents varied in their intended audience and
scope. Some dealt only with the initial assessment and
referral of symptomatic patients and were aimed primar-
ily at primary care practitioners [24, 26, 32–34]. Others
also dealt with definitive diagnosis and treatment, often
devoting more attention to this than initial assessment,
and appeared to have a broader target audience includ-
ing primary care practitioners and specialists [21, 22, 25,
29, 31, 35, 36]. Nine documents were developed for
countries with National/Social Health Insurance Sys-
tems, seven for countries with National Health Services
and two for a country with a Private Healthcare System.
Quality assessment
Two guidance documents scored ≥50% in all six do-
mains (Additional file 1: Table S1). Scores for the Rigour
of Development domain (which appraises the process of
evidence identification, synthesis, assessment and recom-
mendation formulation) ranged from 7 to 96%, with 10
documents scoring ≥50% (Table 1).
Symptoms
All guidance documents provided advice regarding pre-
senting symptoms that should prompt a doctor to con-
sider ovarian cancer. The numbers of guidelines in which
each symptom was included is shown in Fig. 2. One or
more of the related terms bloating, abdominal distention,
increased abdominal size or girth, were listed as symptoms
of ovarian cancer in all documents, abdominal or pelvic
pain in 16 documents, urinary frequency in 14 documents
and feeling full or early satiety in 14 documents. We iden-
tified 20 symptom terms that were included in under 50%
of documents. The number of symptom terms included in
the recommendations of documents ranged from four to
14 (Additional file 1: Table S2). Some documents simply
listed symptoms doctors should be aware of in relation to
ovarian cancer, while others provided further details on
symptom frequency (e.g. > 12x/month), nature (e.g. per-
sistent), duration (e.g. > 1 year) and age at presentation
(e.g. > 50 years).
Physical examinations and signs
Fourteen documents provided guidance on physical
examination or the signs associated with ovarian cancer
(Table 2). Thirteen of these documents specifically
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advocated abdominal examination or mentioned abdom-
inal signs. Nine documents specifically advocated pelvic
or gynaecological examination, three of which detailed
that this should include a speculum examination, three a
bimanual or digital examination and one a vaginal exam-
ination, while three documents recommended a rectal
examination.
Tests
Fifteen documents provided advice on the initial investi-
gation of symptoms and were categorised based on the
number and order of tests recommended (Table 3). One
document advocated a single test strategy, four a duel
testing strategy, four a sequential testing strategy, three
gave multiple testing options, and three did not advocate
testing prior to referral, although two of these did rec-
ommend that a CA125 sample be taken at the point of
specialist referral so as to be available to the specialist.
One document could not be categorised as it was un-
clear when and how tests should be used in the initial
assessment for ovarian cancer [21]. The most commonly
advocated tests for initial investigation were CA125 (11
documents) and ultrasound (12 documents). Several
guidelines also recommended using additional cancer
biomarkers such as CA19–9, CEA, AFP and HCG, rou-
tine blood tests including full blood count and renal
function, imaging tests including CT and MRI, and the
risk tools RMI and ADNEX.
Although the majority of guidelines used symptoms as
the trigger for initiating tests, the two Australian short
guides indicated that testing for ovarian cancer should be
conducted if there was a suspicion on clinical examination
[23, 24]. Conversely, guidelines from Ireland, England,
Scotland, the UK, Sweden and Norway recommended that
concerning findings on examination should prompt an ur-
gent referral to a specialist rather than tests [18, 31–34, 37].
Discussion
In the absence of effective screening programmes, most
women are diagnosed with ovarian cancer following the
Fig. 1 PRISMA flow diagram illustrating the document selection process. *Guidance covered the assessment/management of pre-identified pelvic
masses (N = 11), other aspects of ovarian cancer e.g. treatment (N = 11) and cancers other than ovarian cancer (N = 6)
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Table 1 Characteristics of guidance documents presented by geographical area
Guidance document Development body Publication
date of
current
version
Country and
language if
other than
English
CPG SG CP CS Rigour of
development
(AGREEII) %
Healthcare
system
Continental Europe
Epithelial ovarian carcinoma Dutch Society for Obstetrics
and Gynaecology (NVOG)
2018 Netherlands
(Dutch)
♦ 66 National/
Social
Health
Insurance
Guideline on diagnostics, therapy
and follow-up of malignant ovarian
tumours
The Association of Scientific
Medical Societies in
Germany (AWMF), led by
German Society for
Gynaecology and Obstetrics
(DGGG)
2017 Germany
(German)
♦ 81 National/
Social
Health
Insurance
United Kingdom and Republic of Ireland
Epithelial ovarian / fallopian tube /
primary peritoneal cancer guidelines:
recommendations for practice
British Gynaecological
Cancer Society
2017 UK ♦ 48 National
Health
Service
Ovarian cancer GP referral for
symptomatic women
National Cancer Control
Programme
2016 Republic of
Ireland
♦ 7 National/
Social
Health
Insurance
Suspected cancer: recognition
and referral
National Institute for Health
and Care Excellence (NICE)
2015 England,
Wales,
Northern
Ireland
♦ 96 National
Health
Service
Scottish referral guidelines for
suspected cancer
Healthcare Improvement
Scotland
2014 Scotland ♦ 55 National
Health
Service
Management of epithelial
ovarian cancer
Scottish Intercollegiate
Guidelines Network (Part of
Healthcare Improvement
Scotland)
2013 Scotland ♦ 76 National
Health
Service
Scandinavia
Integrated ovarian cancer
patient pathway
The Danish National Health
Authority
2016 Denmark
(Danish)
♦ 29 National
Health
Service
Ovarian cancer patient pathway The Norwegian Directorate
of Health
2016 Norway
(Norwegian)
♦ 38 National
Health
Service
Standardised ovarian cancer
care pathway a
Regional Cancer Centre Co-
operative Sweden
2015 Sweden
(Swedish)
♦ 55 National
Health
Service
Australasia
Assessment of symptoms that
may be ovarian cancer: a guide
for general practitionersb
Cancer Australia 2015 Australia ♦ 50 National/
Social
Health
Insurance
Appropriate referral of women
with suspected ovarian cancerb
Cancer Australia 2015 Australia ♦ 50 National/
Social
Health
Insurance
Optimal care pathway for women
with ovarian cancer
Cancer Council Victoria 2015 Australia ♦ 10 National/
Social
Health
Insurance
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onset of symptoms [10, 13]. In this review, we identified
and compared international guidance documents on the
initial assessment and investigation for possible ovarian
cancer in symptomatic women. Our results highlight sig-
nificant differences between international guidelines, not
only in the clinical features they suggest should trigger a
suspicion of ovarian cancer, but also in the initial exami-
nations and investigations they advocate.
The stage distribution of ovarian cancer at diagnosis,
and ovarian cancer survival, varies between countries [38].
A positive correlation has been demonstrated between
national survival and the readiness of primary care practi-
tioners to investigate or refer women with symptoms of
possible ovarian cancer [39]. International variation in the
way symptomatic women are assessed and investigated
could also contribute to differences in the timeliness of
ovarian cancer diagnosis and survival. Although guidelines
are not always followed [40], they do influence practice
[41, 42], and variation in international guidelines is likely
to indicate differences in clinical practice internationally.
International comparative research is ongoing to investi-
gate differences in access to tests for ovarian cancer and
survival [43]. Several studies have sought to evaluate the
impact of national urgent cancer referral guidelines on
timeliness of diagnosis and/or survival [42, 44, 45], but
there is little research similarly evaluating the effect of
guidelines which advocate symptom-triggered testing for
ovarian cancer [46]. Studies are needed to evaluate the
impact of such guidance to ensure that the recommended
approaches are effective, for example, by comparing stage
distribution and cancer survival pre- and post- implemen-
tation of guidance. Comparing the impact of cancer detec-
tion guidelines between countries is challenging, not least
as it relies on the use of standardised endpoints (stage,
survival) which are not always uniformly recorded. Initia-
tives such as the International Cancer Benchmarking Part-
nership [43], may improve consistency in the recording of
such outcomes and so aid international comparisons.
Guideline developers have to consider the healthcare
system for which they are developing guidance. The
guidance from countries with National Health Services
was, in general, specific on symptoms and signs and gave
clear recommendations on which tests should be per-
formed and in what order. In contrast, guidance from
the USA, which has a Private Healthcare System, was
much less prescriptive, providing different options for
the clinician. This is likely to reflect the fact that Na-
tional Health Services aim to provide uniform services
and level of care across a country/region and must plan
for this, while the care provided in a country with a
Private Healthcare System may differ depending on the
private provider. Similarly, guideline recommendations
Table 1 Characteristics of guidance documents presented by geographical area (Continued)
Guidance document Development body Publication
date of
current
version
Country and
language if
other than
English
CPG SG CP CS Rigour of
development
(AGREEII) %
Healthcare
system
Suspected cancer in primary care:
Guidelines for investigation, referral
and reducing ethnic disparity
New Zealand Guidelines
Group
2009 New
Zealand
♦ 56 National/
Social
Health
Insurance
North America
Ovarian cancer: including fallopian tube
cancer and primary peritoneal cancer
National Comprehensive
Cancer Network
2018 (v2) USA ♦ 65 Private
Health
System
The role of the obstetrician-gynaecologist
in the early detection of epithelial ovarian
cancer in women at average risk
American College of
Obstetrician Gynaecologists
and the Society of
Gynaecological Oncology
2017 USA ♦ 11 Private
Health
System
Ovarian cancer diagnosis pathway map Cancer Care Ontario 2016 Ontario,
Canada
♦ 19 National/
Social
Health
Insurance
Genital tract cancers in females: ovarian,
fallopian tube, and primary peritoneal
cancers
Guidelines and Protocol
Advisory Committee
(Medical Services
Commission)
2014 British
Columbia,
Canada
♦ 16 National/
Social
Health
Insurance
CPG Clinical Practice Guideline, SG Short Guideline, CP Clinical Pathway, CS Consensus Statement
aA full clinical practice guideline covering initial assessment, definitive diagnosis and treatment [18], and a short version focussing on initial assessment and
investigation in primary care [19], are available. Guidance on initial assessment differed slightly between the two documents. The recommendations presented in
this review were extracted from the short guide. AGREEII appraisal included an assessment of the full guideline evidence review
bShort guide, still active. Based on a now rescinded 2004 full clinical practice guideline entitled ‘Clinical practice guidelines for the management of women with
ovarian cancer’ [20]. AGREEII appraisal included an assessment of the full guideline evidence review
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may be influenced by the speciality of the clinician per-
forming the initial assessment within a healthcare system
e.g. GP/family physician and/or gynaecologist. Gynaecol-
ogists may be more competent with, and willing to per-
form, gynaecological examinations and better equipped
to interpret complex tests and algorithms. Direct access
to gynaecologists is available in the USA and Germany
and guidance from these countries included a range of
specialist tests [47, 48]. In contrast, in countries like the
UK, Ireland, Australia and Scandinavia, where GPs play
a strong gatekeeping role and where a referral is gener-
ally required prior to gynaecology assessment, a limited
number of tests were recommended.
Over the last 15 years a number of studies have ex-
plored associations between ovarian cancer and symp-
toms; however, differences exist between the symptoms
they have identified and their predictive values. Most
documents in this review included symptoms widely
regarded as increasing the likelihood of an ovarian can-
cer being present, for example, abdominal distension
and pelvic pain [4, 5, 49]. Some documents also included
symptoms such as fatigue, nausea, back pain and the
generic term ‘urinary symptoms’, which are more con-
troversial, and were not found to increase the likelihood
of ovarian cancer in a recent comprehensive systematic
review [49]. Some variation may be due to the type of
evidence that guideline developers chose to consider.
For example, UK guideline developers appear to have
taken account of all relevant international studies when
deciding which symptoms should be included in the
guidance [8]. In contrast, USA guidelines included a
more restricted list of symptoms derived from the influ-
ential Ovarian Cancer Symptom Index which was devel-
oped in the USA [50]. As almost all published studies
exploring associations between ovarian cancer and
symptoms have been undertaken in the UK and the
USA, guideline developers outside these countries must
rely on international evidence to inform their recom-
mendations [49]. Further large, high quality research
studies, undertaken in countries around the world,
would improve our understanding of the symptomology
of ovarian cancer and help resolve disagreements over
which symptoms should be included in guidelines.
Given the range of AGREEII scores guidelines obtained
in the Rigour of Development domain, discrepancies in
symptoms and other recommendations are likely stem in
part from differences in the scope and quality of evidence
reviews undertaken by guideline developers. It is likely
that where a rigorous systematic approach is not followed,
important research, for example on symptoms, may be
missed. All guidance documents in this review are likely
to influence patient care and should be developed rigor-
ously and be explicit about the development process.
Different strategies could help encourage this, which in
Fig. 2 Symptoms included in guidelines
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Table 2 Physical examinations recommended and ovarian cancer signs noted within guidance documents
Document Type of examination specified Signs
Continental Europe
Epithelial ovarian carcinoma (Neth) Not specified - Pelvic mass / abdominal mass
- Ascites
- Pleural effusion
- Increased uterine / vaginal prolapse
- Enlarged supraclavicular lymph nodes
Guideline on diagnostics, therapy and follow-up of
malignant ovarian tumours (Ger)
Abdominal and pelvic / gynaecological
examination (including digital and speculum)
- Ovarian mass
United Kingdom and the Republic of Ireland
Epithelial Ovarian / Fallopian Tube / Primary
Peritoneal Cancer Guidelines: recommendations for
practice (UK)
Examination - Pelvic or abdominal mass
Suspected cancer: recognition and referral (Eng) Physical examination - Ascites
- Pelvic / abdominal mass (not obviously
uterine fibroids)
Ovarian cancer GP referral for symptomatic women
(Ire)
Clinical examination (include a
bimanual-pelvic examination)
- Unexplained ascites
- Pelvic mass
- Palpable ovaries in postmenopausal
women
Scottish referral guidelines for suspected cancer
(Scot)a
Abdominal palpation - Ascites
- Pelvic or abdominal mass (not
obviously uterine fibroids,
gastrointestinal or urological in origin)
Management of epithelial ovarian cancer (Scot) Not specified - Not specified
Scandinavia
Integrated ovarian cancer patient pathway (Den) Gynaecological examination
(including palpation and speculum)
- Ascites
- Pelvic mass
Ovarian cancer patient pathway (Nor) Not specified - Not specified
Standardised ovarian cancer care pathway (Swed)b Palpation of superficial lymph nodes, abdominal
palpation, rectal examination and auscultation
of the heart and lungs
- Pleural effusion (unexplained)
- Ascites
Australasia
Assessment of symptoms that may be ovarian
cancer: a guide for general practitioners (Aus)
Abdominal palpation, pelvic assessment,
vaginal and rectal examination
- Firm resistance on abdominal palpation
- Unexplained fullness
-Fullness + shifting dullness on
percussion
- Hard irregular mass in the pouch of
Douglass
- Adnexal mass
Appropriate referral of women with suspected
ovarian cancer (Aus)
Not specified - Not specified
Optimal care pathway for women with ovarian
cancer (Aus)
General and pelvic examination - Not specified
Suspected cancer in primary care: guidelines for
investigation, referral and reducing ethnic disparity
(NZ)
Abdominal palpation and pelvic examination - Not specified
North America
Ovarian cancer: including fallopian tube cancer and
primary peritoneal cancer (USA)
Abdominal and pelvic examination - Suspicious palpable pelvic or abdominal
mass
- Ascites or abdominal distension
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turn could help to harmonise symptoms in international
guidelines. For example, funders could have guidelines in-
dependently appraised following development, using the
AGREEII checklist, and publish the results alongside the
guidelines. In addition, many guidelines are published in
peer reviewed journals. Guideline developers could be re-
quired to submit an AGREEII style checklist as part of the
submission process. While not all guideline development
groups have the significant resources required to develop
all elements of clinical guidelines de novo, this may not be
necessary. For example, the guidance from the New
Zealand Guideline Group was based on 2005 NICE guid-
ance and adapted to suit the New Zealand healthcare sys-
tem. Collaboration by international guideline producers
on aspects of guidelines such as symptoms, which are
likely to differ little between healthcare systems or coun-
tries, could also help reduce duplication, ensure quality
and increase consistency.
A pelvic or gynaecological examination was specifically
recommended by half of the guidelines, with three speci-
fying that a speculum and three a bimanual or digital
examination, be performed. However, Myres et al.’s re-
view, which included studies on examinations performed
by gynaecologists pre-surgery and in the screening
setting, found that less than half of adnexal masses are
picked up on bimanual examination [51]. GPs might be
less skilled at identifying pelvic masses, but a recent re-
view identified no studies evaluating their competence
at performing pelvic examinations for gynaecological
cancer [52].
Most documents recommended the use of ultrasound
and/or CA125 in the initial investigation for ovarian
cancer. However, guidelines varied in the sequence of
testing, and a variety of other serum biomarkers, im-
aging modalities and risk algorithms were included in
some. This variation may result in part from differences
in the funding and available resources within different
healthcare systems. For example, consideration of costs
and resource implications played a role in the decision
by NICE to recommend the relatively cheap and widely
accessible CA125 test rather than ultrasound as the first
line investigation [8]. There is little high quality evidence
for tests used in the initial investigation of possible ovar-
ian cancer [8], often necessitating consensus opinion
[34, 35], with one guideline making no recommenda-
tions on testing because of the lack of evidence [26].
Evidence from secondary care and screening studies in-
dicates that CA125 and ultrasound differ in their diagnos-
tic accuracy [8, 53, 54]. Therefore, the test(s) chosen, and,
where they are used in combination, the order of testing,
may have important implications for cancer detection. For
example, a sequential testing approach, where both tests
need to be abnormal to trigger specialist referral [33], will
be more specific at the cost of lower sensitivity. Con-
versely, a dual-testing approach, where an abnormality in
either test warrants referral [34, 35], will be more sensitive
but sacrifices specificity and economy.
This is the first study to systematically identify and
compare international guidance documents on the initial
assessment and investigation for possible ovarian cancer
in symptomatic women. Direct comparisons between
the testing strategies employed in different countries
must be interpreted with reference to the healthcare
system for which the guidance was produced. Although
we performed a comprehensive literature search, it is
possible that we did not identify all relevant guidance
documents e.g. healthcare guidelines not published on-
line or not available outside the region or country of
publication. We attempted to obtain all relevant docu-
mentation on the development process of guidelines in-
cluded in this review, contacting guideline producers for
additional information when necessary, to allow us to
perform comprehensive AGREEII appraisals. However, it
is possible that we did not gain access to all relevant
documents e.g. unpublished search strategies or evidence
reviews.
Table 2 Physical examinations recommended and ovarian cancer signs noted within guidance documents (Continued)
Document Type of examination specified Signs
The role of the obstetrician-gynaecologist in the
early detection of epithelial ovarian cancer in
women at average risk (USA)
Not specified - Not specified
Ovarian cancer diagnosis pathway map (Ont, Can) Directed physical examination. Pelvic examination
including speculum and bimanual examinations
and examination of the external genitalia
- Suspicious palpable pelvic or abdominal
mass
- Ascites
Genital tract cancers in females: ovarian, fallopian
tube, and primary peritoneal cancers (BC, Can)
A physical examination of the abdomen and
pelvis including a pelvi-rectal examination
- Abdominal mass
aAs recorded on associated Microsite and Short guidance document. The full guideline covers all gynaecological cancers with examinations and findings listed
together. Microsite and Short guideline lists examinations and signs by cancer site
bBoth a full clinical practice guideline covering initial assessment, definitive diagnosis and treatment, and a short version focusing on initial assessment and
investigation in primary care, are available. Guidance on initial assessment differed slightly between the two documents. The presented data was extracted from
the short guide
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Table 3 Summary of tests recommended for the assessment of symptoms and/or signs of ovarian cancer
Strategy Guideline When is testing advocated? Initial tests
Single test Guideline on diagnostics, therapy and
follow-up of malignant ovarian tumours
(Ger)
Signs or symptoms of ovarian cancer
(OC)
Transvaginal US
Note: CT, MRI, PET CT may be used in
specific cases
Dual testing Scottish referral guidelines for suspected
cancer (Scot)
Symptoms of OC
Note: Ascites- refer urgently rather than
test
CA125 + pelvic US
Management of epithelial ovarian cancer
(Scot)
Symptoms of OC CA125 + pelvic US
Assessment of symptoms that may be
ovarian cancer: a guide for general
practitioners (Aus)
Mass identified clinically
Note: No mass identified clinically- refer
appropriately
CA125 + transvaginal US Or
CA125 + Abdominal US Or
CA125 + CT
Appropriate referral of women with
suspected ovarian cancer (Aus)
Suspicious findings on clinical
examination
CA125 + transvaginal US +/− calculation
of Risk of Malignancy Index (RMI)
Sequential testing Suspected cancer: recognition and referral
(Eng)
OC symptoms
Note: Ascites or suspicious mass- refer
urgently rather than test
First line: CA125
Second line: Abdominopelvic US (if CA125
is abnormal)
Epithelial ovarian / fallopian tube / primary
peritoneal cancer guidelines:
recommendations for practice (UK)
OC symptoms
Note: Pelvic or abdominal mass- refer
urgently rather than test
First line: CA125
Second line: Abdominopelvic US (if CA125
is abnormal)
Ovarian cancer GP referral for symptomatic
women
(Ire)
History suspicious of OC but
examination normal
Note: Suspicious pelvis mass or ascites-
refer urgently rather than test
First line: CA125
Second line: US of pelvis (If CA125 35–200
u/ml)
Note: If CA125 > 200 u/ml refer without
US
Ovarian cancer diagnosis pathway map
(Ont, Can)
Suspicion of OC
Note: Tests may be performed prior to
specialist referral but are not a
requirement for referral. Can refer prior to
testing
First line: Transvaginal US and / or other
imaging
Second line: CA125, FBC, Renal Function +
RMI
(If indicated: CEA, CA19–9, other tumour
markers e.g. AFP, LDH, HCG)
Multiple testing
options
Optimal care pathway for women with
ovarian cancer (Aus)
Symptoms of OC Pelvic US +
Routine blood tests +
CA125 +
Algorithms such as RMI, ADNEX +/−
CT scan
Genital tract cancers in females: ovarian,
fallopian tube, and primary peritoneal
cancers (BC, Can)
Suspicion of OC
Note: Imaging not essential for referral
Transvaginal or abdominal US
Blood tests: CA125, CA19–9, CA15–3, CEA
< 40 yrs old: AFP, HCG, LDH
Ovarian cancer Including fallopian tube
cancer and primary peritoneal cancer
(USA)
Suspicion of OC
Note: Provides some advice on when
particular tests are indicated. Appears to
include both initial and pre-surgical tests
US and/or abdominal/pelvic CT/MRI (as
indicated)
Chest CT or chest x-ray (as indicated)
Complete blood count, chemistry profile
and LFT
CA125 or other tumour markers (as
indicated: inhibin, β-hCG, AFP, LDH, CEA,
CA19–9)
Nutritional status
GI evaluation (as indicated)
No testing prior to
referral
Integrated ovarian cancer patient pathway
(Den)
At point of specialist referral Note CA125 requested in primary care at
time of referral so as to be available to the
specialist. Not acted upon in primary care
Ovarian cancer patient pathway (Nor) Post specialist referral Post referral
Standardised ovarian cancer care pathway
(Swed)
At point of specialist referral Note CA125 requested in primary care at
time of referral so as to be available to the
specialist. Not acted upon in primary care
Unclear or no
recommendations
on testing given
Suspected cancer in primary care:
guidelines for investigation, referral and
reducing ethnic disparity (NZ)
No recommendations No recommendations
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Conclusion
Multiple international guidance documents provide advice
on the initial assessment and investigation for possible
ovarian cancer in symptomatic women. These documents
differ markedly in the symptoms they include and the
physical examinations and clinical investigations they rec-
ommend. Given this, it is probable that patient care and
the likelihood of cancer detection will vary depending on
the guidance document followed. Studies evaluating the
role of examinations and the diagnostic performance of
testing strategies for the initial assessment of possible
ovarian cancer in symptomatic women are needed to aid
the development of more evidence-based guidelines.
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